Feb 18, 2020
Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions
Feb 03, 2020
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin
Dec 19, 2019
Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models
Dec 04, 2019
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Nov 19, 2019
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Nov 13, 2019
Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer
Nov 12, 2019
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial
Oct 29, 2019
Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models
Sep 16, 2019
Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery
Aug 20, 2019
Moleculin Announces CTRC Approval of WP1066 Pediatric Brain Tumor Trial
Aug 13, 2019
Moleculin Announces Completion of Lymphoma Trial Enrollment
Aug 06, 2019
Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models
Jul 18, 2019
Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort
Jul 10, 2019
Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation
Apr 23, 2019
Moleculin Announces $15.0 Million Registered Direct Offering
Apr 18, 2019
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin
Apr 17, 2019
Moleculin Announces Significant Discovery in Lung Cancer Models
Apr 11, 2019
Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial
Apr 09, 2019
Moleculin Announces Successful Expansion of its Leukemia Drug Program
Mar 27, 2019
Moleculin Announces Pricing Of Underwritten Public Offering